%0 Journal Article
%T Omega-3 polyunsaturated fatty acids in the treatment of patients with cardiovascular diseases
%A A.V. Govorin
%A A.P. Filev
%J Rational Pharmacotherapy in Cardiology
%D 2012
%I Rational Pharmacotherapy in Cardiology
%X For today there are convincing evidences of beneficial effect of ¦Ø-3 polyunsaturated fatty acids (PUFA) - eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids ¨C in a number of cardiovascular diseases. Efficacy of ¦Ø-3 PUFA was confirmed by results of the large-scale clinical trials. Data on ¦Ø-3 PUFA efficacy in heart failure and cardiac arrhythmia were received, besides their well-known hypolipidemic effect. Low level of ¦Ø-3 PUFA biomarker, ¦Ø-3 index (content of EPA and DHA in erythrocytes), is considered as a risk factor of coronary heart disease as well as a risk factor of fatal arrhythmias. Use of standardized medicinal product with high content of EPA and DHA leads to the positive therapeutic effect in patients with different cardiovascular diseases.
%K ¦Ø-3 polyunsaturated fatty acids
%K heart failure
%K arrhythmia.
%U http://www.rpcardio.com/archive/article.php?ID=3511